Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

rm vs. Pegasys arm].

-- Safety and tolerability were similar among the three treatment groups, with no new peginterferon or ribavirin related adverse events identified in this large study. Overall adverse events reported for the three treatment regimens were similar. As seen in other studies with these treatments, a range of "flu-like symptoms" were the most commonly reported adverse events for all three treatment regimens. Overall, the proportion of patients reporting serious adverse events was similar (9 vs. 9 vs. 12 percent, respectively). Discontinuation rates due to adverse events were similar across the three treatment arms (13 vs. 10 vs. 13 percent, respectively) as were discontinuations due to psychiatric adverse events (3 vs. 2 vs. 2 percent, respectively).

The complete results of the IDEAL study will be submitted for peer-reviewed publication, as well as to health authorities worldwide.

About IDEAL

The IDEAL study was undertaken by Schering-Plough as an important step in meeting the needs of the hepatitis C medical and patient communities to identify improved treatment strategies to optimize outcomes for patients. IDEAL, a Phase IIIb, randomized, parallel-group study, was conducted at 118 academic and community centers across the United States. The study treated 3,070 adult patients with chronic HCV genotype 1. Of these, 82 percent of patients had high viral load (greater than 600,000 IU/mL),(3) 11 percent had grade F3/4 fibrosis/cirrhosis, and 19 percent were African Americans. There were no significant differences in patient demographics or disease characteristics across the three treatment arms.

The comparison of the two PEGINTRON combination therapy doses (1.5 vs. 1.0 mcg/kg/week) was conducted as a post-approval commitment to the U.S. Food and Drug Administration (FDA). The comparison of the PEGINTRON and Pegasys combination therapy regimens was added to the study because no randomized, controlled head-to-head study
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Hill-Rom (NYSE: ... Providence Health ( Renton, WA ), the ... expands the companies, existing relationship as Hill-Rom now becomes ... Bariatric capital bed frame and surface products. ... systems in the U.S.  It operates 34 hospitals, 475 ...
(Date:9/23/2014)... Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced ... Resnick have been elected to Medimetriks, Board ... Mr. Lary, who will serve on Medimetriks, Audit ... experience to the Company.  Mr. Lary is currently ... a leading institutional investment firm.  Mr. Lary is ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... MARINO, Calif. March 25, 2011 VG Energy, ... VRAL ), announced today that it ... to verify lab results on a large scale for the development ... VG Energy has developed proprietary technology, with results ...
... Ltd. (Nasdaq: SVA ), a leading provider ... Weidong Yin, President and CEO, and Ms. Helen Yang, ... UBS Greater China Healthcare Corporate Day.  The conference will ... March 28th to March 29.  The Sinovac team will ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Sinovac Participates in UBS Greater China Healthcare Corporate Day 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 Mel Frank, ... about cultivating, growing and harvesting marijuana. He is perhaps ... the field and he’ll be leading a special elective ... am to 5:00 pm at Oaksterdam University ... law, botany and nomenclature, harvesting and manicuring, and identifying ...
(Date:9/23/2014)... that FDG-PET technology is less accurate in diagnosing ... infections like histoplasmosis or tuberculosis are common. ... lead to unnecessary tests and surgeries for patients, ... Histoplasmosis and other fungal diseases are linked to ... and are found in soils. , The study ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... 2014 (HealthDay News) -- A test used to diagnose lung ... certain lung infections are more common, a new analysis says. ... through the use of what,s known as functional imaging. For ... is used, according to the study authors. Cancerous tumors ... parts of the lungs that don,t have cancer, according to ...
(Date:9/23/2014)... 23, 2014 Grinnell Mutual seeks ... projects in the Midwest. Working Together Making It ... non-profit organizations with projects positively impacting their communities. ... marketplace make their communities a better places,” said ... Community Relations Barb Baker. “Their leadership—as coaches, as ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Study questions accuracy of lung cancer screens in some geographic regions 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... death rates, longer hospital stays and greater costs , , ... (GI) bleeding admitted to hospitals on weekends are more ... to two studies that analyzed U.S. patient data. ... upper gastrointestinal hemorrhage (NVUGIH) admitted on weekends were 36 ...
... of Your Mental Health Talk Radio www.blogtalkradio.com/yourmentalhealth when ... Men Are From Mars, Women Are From Venus ... new book When Mars and Venus Collide: Improving Relationships ... on Thursday, March 5th at 8 PM EST/5 PM ...
... Hit Unprecedented Lows; Approximately Half of Hospitals UnprofitableANN ... margin of U.S. hospitals has fallen to zero ... hospital finances published today. Driven largely by ... apparent in all types of hospitals - small, ...
... than 52,000 patients from eight countries has shown that ... improvements and greater patient satisfaction. , The findings, ... International Journal of Clinical Practice , show that 53 ... less than seven per cent, the target set by ...
... users with Zix CorporationDALLAS, March 2 Zix Corporation ... Blue Shield of Massachusetts (BCBSMA) today announced a contract ... Zix Corporation and Blue Cross Blue Shield of Massachusetts ... entering its sixth year. Under the contract terms, ...
... Edwin Ishoo , MD, an Otolaryngologist and facial ... the use of both minimally invasive and non-invasive techniques ... procedures implemented by Dr. Ishoo are also designed to ... activities as soon as possible."We are committed to using ...
Cached Medicine News:Health News:Weekend Admission May Be Riskier for GI Bleeding 2Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 2Health News:Thomson Reuters Study Tracks Impact of Recession on Hospitals 3Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Zix Corporation and Blue Cross Blue Shield of Massachusetts Expand the Industry's Largest e-Prescribing Program 2Health News:Edwin Ishoo MD Providing Non-Invasive Cosmetic Procedures, Minimizing Recovery Time 2
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps : Asymmetrical Endgripping Forceps...
Pic forceps design that is slightly curved; tips have special "surface treatment" for enhanced manipulation of the retina....
Microforceps : Eckardt Endgripping Forceps...
Medicine Products: